Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary DiseaseBethesda, MDGOLD2017
   Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• SchroeckensteinDCBushRKChervinskyPBusseWWTwelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolateJ Allergy Clin Immunol19888211151193392363
   PubMed Web of Science ®Google Scholar
• WalkerFBKaiserDLKowalMBSurattPMProlonged effect of inhaled glycopyrrolate in asthmaChest198791149513792086
   PubMed Web of Science ®Google Scholar
• JohnsonBESurattPMGalTJWilhoitSCEffect of inhaled glycopyrrolate and atropine in asthma: precipitated by exercise and cold air inhalationChest19848533253286697786
   PubMed Web of Science ®Google Scholar
• FoodUSAdministrationDrugSeebri Neohaler [prescribing Information]2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207923lbl.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyEuropean public assessment report: Seebri Breezhaler2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdfAccessed March 20, 2018
   Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• RackéKMatthiesenSThe airway cholinergic system: physiology and pharmacologyPulm Pharmacol Ther200417418119815219263
   PubMed Web of Science ®Google Scholar
• FrankoBVLunsfordCDDerivatives of 3-pyrrolidinols – III: the chemistry, pharmacology, and toxicology of some N-substituted-3-pyrrolidyl α-substituted phenylacetatesJ Med Pharm Chem1960252354013701449
   PubMedGoogle Scholar
• BarnesPJAnticholinergicsCelliBRPharmacotherapy in Chronic Obstructive Pulmonary DiseaseNew YorkMarcel Dekker2004201216
   Google Scholar
• BartelsCLoobyMSechaudRKaiserGDetermination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approachBr J Clin Pharmacol201376686887923506208
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRLeighton-DaviesJThe influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropiumJ Pharmacol Exp Ther2012343252052822854200
   PubMed Web of Science ®Google Scholar
• KaltialaEPenttiläAVapaataloHLarmiTThe fate of intravenous (3H) glycopyrrolate in manJ Pharm Pharmacol19742653523544153115
   PubMed Web of Science ®Google Scholar
• SechaudRRenardDZhang-AubersonLde la MotteSDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther201250211812822257577
   PubMed Web of Science ®Google Scholar
• GavaldàARamosICarcasonaCThe in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromidePulm Pharmacol Ther201428211412124928173
   PubMed Web of Science ®Google Scholar
• HanselTTBarnesPJTiotropium bromide: a novel once-daily anti-cholinergic bronchodilator for the treatment of COPDDrugs Today (Barc)200238958560012582447
   PubMed Web of Science ®Google Scholar
• OgodaMNiiyaRKoshikaTYamadaSComparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolateJ Pharmacol Sci2011115337438221358117
   PubMed Web of Science ®Google Scholar
• RoglianiPCalzettaLOraJPharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchiEur J Pharmacol201576138339025952728
   PubMed Web of Science ®Google Scholar
• SentellasSRamosIAlbertiJAclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolitesEur J Pharm Sci201039528329020093184
   PubMed Web of Science ®Google Scholar
• RamosFLKrahnkeJSKimVClinical issues of mucus accumulation in COPDInt J Chron Obstruct Pulmon Dis2014913915024493923
   PubMed Web of Science ®Google Scholar
• GosensRZaagsmaJMeursHHalaykoAJMuscarinic receptor signaling in the pathophysiology of asthma and COPDRespir Res200677316684353
   PubMed Web of Science ®Google Scholar
• MelloniBGermoutyJThe influence of a new β-agonist: formoterol on mucociliary functionRev Mal Respir199295503507 French1439090
   PubMed Web of Science ®Google Scholar
• LindbergSKhanRRunerTThe effects of formoterol, a long-acting β2-adrenoceptor agonist, on mucociliary activityEur J Pharmacol199528532752808575514
   PubMed Web of Science ®Google Scholar
• RestrepoRDInhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?Respir Care20075291159117317716384
   PubMed Web of Science ®Google Scholar
• TagayaEYagiOSatoAEffect of tiotropium on mucus hypersecretion and airway clearance in patients with COPDPulm Pharmacol Ther201639818427350218
   PubMed Web of Science ®Google Scholar
• HasaniATomsNAgnewJESarnoMHarrisonAJDilworthPThe effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPDChest200412551726173415136383
   PubMed Web of Science ®Google Scholar
• MeyerTReitmeirPBrandPEffects of formoterol and tiotropium bromide on mucus clearance in patients with COPDRespir Med2011105690090621397483
   PubMed Web of Science ®Google Scholar
• BennettWDChapmanWFMascarellaJMThe acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPDChest199310324884958432142
   PubMed Web of Science ®Google Scholar
• HugelHEllershawJGamblesMRespiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromideJ Palliat Med20069227928416629557
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationMedical review: glycopyrrolate2009 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022571Orig1s000MedR.pdfAccessed March 20, 2018
   Google Scholar
• MirakhurRKDundeeJWJonesCJEvaluation of the anticholinergic actions of glycopyrronium bromideBr J Clin Pharmacol1978517784619938
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySeebri Breezhaler [summary of product characteristics]2012 Available from: https://www.medicines.org.uk/emc/medicine/27138Accessed March 20, 2018
   Google Scholar
• AstraZeneca PharmaceuticalsLPBevespi Aerosphere [prescribing information]2016 Available from: https://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyUltibro Breezhaler [summary of product characteristics]2016 Available from: https://www.medicines.org.uk/emc/medicine/29533Accessed March 20, 2018
   Google Scholar
• US Food and Drug AdministrationUtibron Neohaler [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drug-satfda_docs/label/2015/207930s000lbl.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyTrimbow [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004257/WC500233163.pdfAccessed March 20, 2018
   Google Scholar
• KerwinEDonohueJFGoodinTTosielloRWheelerAFergusonGTEfficacy and safety of glycopyrrolate/eFlow CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trialsRespir Med201713223825028838685
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Trimbow [initial authorization]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004257/WC500228080.pdfAccessed March 20, 2018
   Google Scholar
• ArievichHOverendTRenardDA novel model-based approach for dose determination of glycopyrronium bromide in COPDBMC Pulm Med2012127423217058
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• SekiyaMKawayamaTFukuchiYSafety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trialEur Respir J201240Suppl 56P2013
   Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
   PubMed Web of Science ®Google Scholar
• WangCSunTHuangYEfficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 studyInt J Chron Obstruct Pulmon Dis201510576825609940
   PubMed Web of Science ®Google Scholar
• MarinJMBeehKMClemensAEarly bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary Function in the Morning)Int J Chron Obstruct Pulmon Dis2016111425143427418815
   PubMed Web of Science ®Google Scholar
• LaForceCFeldmanGSpangenthalSEfficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 studyInt J Chron Obstruct Pulmon Dis2016111233124327354782
   PubMed Web of Science ®Google Scholar
• KerwinESilerTMKorenblatPEfficacy and safety of twice-daily glycopyrrolate versus placebo in patients with COPD: the GEM2 studyChronic Obstr Pulm Dis20163254955928848879
   PubMedGoogle Scholar
• MahlerDAGiffordAHSattiALong-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3)Respir Med2016115394527215502
   PubMed Web of Science ®Google Scholar
• FergusonGTGoodinTTosielloRWheelerAKerwinELong-term safety of glycopyrrolate/eFlow CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized studyRespir Med201713225126028919143
   PubMed Web of Science ®Google Scholar
• FabbriLMKerwinEMSpangenthalSDose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDRespir Res201617110927586537
   PubMed Web of Science ®Google Scholar
• KarabisALindnerLMocarskiMHuismanEGreeningAComparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2013840542324043936
   PubMed Web of Science ®Google Scholar
• IsmailaASHuismanELPunekarYSKarabisAComparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysisInt J Chron Obstruct Pulmon Dis2015102495251726604738
   PubMed Web of Science ®Google Scholar
• Lechuga-BallesterosDNogaBVehringRCummingsRHDwivediSKNovel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem20113131703171821942257
   PubMed Web of Science ®Google Scholar
• VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
   PubMed Web of Science ®Google Scholar
• KerwinEMSpangenthalSKollarCRoseEStReisnerCA phase IIB randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPDRespir Res20181913829506504
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGThe effective treatment of COPD: anticholinergics and what else?Drug Discov Today Ther Strateg200633277286
   Google Scholar
• BarisioneGBaroffioMCrimiEBrusascoVBeta-adrenergic agonistsPharmaceuticals (Basel)2010341016104427713285
   PubMedGoogle Scholar
• MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using Co-Suspension Delivery Technology in patients with COPDChest2017151234035727916620
   PubMed Web of Science ®Google Scholar
• HananiaNATashkinDPKerwinEMLong-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary diseaseRespir Med201712610511528427541
   PubMed Web of Science ®Google Scholar
• ReisnerCGottschlichGFakihF24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPDRespir Res20171815728821260
   PubMed Web of Science ®Google Scholar
• MartinezFJFabbriLMFergusonGTBaseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPDChest201715261169117828720336
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• KardosPHagedorn-PeinzIThe impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study: the FAVOR studyInt J Chron Obstruct Pulmon Dis201813697729317812
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• FergusonGTTaylorAFThachCLong-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 studyChronic Obstr Pulm Dis20163471672828848898
   PubMedGoogle Scholar
• KerwinEFergusonGTSanjarSDual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studiesLung2017195673974728993871
   PubMed Web of Science ®Google Scholar
• VogelmeierCZhongNHumphriesMJIndacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysisInt J Chron Obstruct Pulmon Dis2016113189319728008244
   PubMed Web of Science ®Google Scholar
• WatzHMailänderCBaierMKirstenAEffects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (the MOVE study)BMC Pulm Med20161619527301417
   PubMed Web of Science ®Google Scholar
• FrithPAThompsonPJRatnavadivelRGlycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialThorax201570651952725841237
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• GershonACroxfordRCalzavaraACardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary diseaseJAMA Intern Med2013173131175118523689820
   PubMed Web of Science ®Google Scholar
• FoodUSAdministrationDrug Lonhala Magnair [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208437lbl.pdfAccessed March 20, 2018
   Google Scholar
• Boehringer Ingelheim Spiriva HandiHaler [prescribing information]2016 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva/Spiriva.pdfAccessed March 20, 2018
   Google Scholar
• Boehringer IngelheimSpiriva Respimat [prescribing information]2017 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdfAccessed March 20, 2018
   Google Scholar
• Boehringer IngelheimStiolto Respimat [prescribing information]2016 Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines Agency Spiolto Respimat [summary of product characteristics]2015 Available from: https://www.medicines.org.uk/emc/medicine/30495Accessed March 20, 2018
   Google Scholar
• European Medicines AgencyIncruse [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002809/WC500167430.pdfAccessed March 20, 2018
   Google Scholar
• GlaxoSmithKlineIncruse Ellipta [prescribing information]2017 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDFAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyAnoro [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdfAccessed March 20, 2018
   Google Scholar
• GlaxoSmithKlineAnoro Ellipta [prescribing information]2013 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203975s000lbl.pdfAccessed March 20, 2018
   Google Scholar
• GlaxoSmithKlineTrelegy Ellipta [prescribing information]2017 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trelegy/pdf/TRELEGY-PI-MG-IFU.PDFAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyEklira Genuair [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002211/WC500132661.pdfAccessed March 20, 2018
   Google Scholar
• AstraZeneca PharmaceuticalsLPTudorza Pressair [prescribing information]2012 Available from: http://www.azpicentral.com/tudorza/pi_tudorza.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyBretaris Genuair [summary of product characteristics]2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002706/WC500132732.pdfAccessed March 20, 2018
   Google Scholar
• European Medicines AgencyDuaklir Genuair [summary of product characteristics]2017 Available from: https://ec.europa.eu/health/documents/community-register/2014/20141119130022/anx_130022_en.pdfAccessed March 20, 2018
   Google Scholar
• Theravance BiopharmaRevefenacin peak inspiratory flow rate (PIFR) study in COPD Available from: https://clinicaltrials.gov/ct2/show/NCT3095456. NLM identifier: NCT3095456Accessed March 20, 2018
   Google Scholar
• Theravance BioPharmaTheravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease2017 Available from: http://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-and-mylan-submit-new-drug-application-fdaAccessed March 20, 2018
   Google Scholar